VEGFR, RET, and RAF/MEK/ERK Pathway Take Part in the Inhibition of Osteosarcoma MG63 Cells with Sorafenib Treatment

The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib

(2012) Wei-feng Mao et al.   ACTA PHARMACOLOGICA SINICA

Mitogen-activated protein kinases in hepatocellular carcinoma development

(2010) Lihua Min et al.   SEMINARS IN CANCER BIOLOGY

Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer

(2009) Axel S Merseburger et al.   Expert Review of Anticancer Therapy

Advances in Target Therapy for Lung Cancer

(2009) T. Mitsudomi   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line

(2009) B. Wolfesberger et al.   RESEARCH IN VETERINARY SCIENCE

Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

(2008) Michael C. Heinrich et al.   JOURNAL OF CLINICAL ONCOLOGY